| Abstrakt: |
Researchers at Sungkyunkwan University in Suwon, South Korea, have developed a steroid derivative, SG13-136, that shows dual inhibitory activity against AIMP2 and a-synuclein, proteins associated with Parkinson's disease (PD). This compound demonstrated strong binding affinity and inhibitory function for both proteins without estrogenic activity or toxicity in vivo. The study suggests that targeting both AIMP2 and a-synuclein could be an effective treatment strategy for PD, offering potential insights for drug discovery in the future. [Extracted from the article] |
